阿立哌唑与硫必利对抽动障碍患儿疗效及T淋巴细胞亚群、神经递质的影响

Effects of aripiprazole and tiapride on the curative effect, T lymphocyte subsets and neurotransmitters in children with tic disorder

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2024, 51(2)
作者
作者单位

佳木斯市精神病医院精神科 ;

摘要
【摘要】 目的:对比分析阿立哌唑与硫必利治疗抽动障碍患儿对疗效及T淋巴细胞亚群、神经递质的影响。方法:选我院2020年9月至2022年9月收入的抽动障碍患儿76例为研究对象,按照随机数表法将其分为阿立哌唑组(38例)、硫必利组(38例),阿立哌唑组接受阿立哌唑片治疗,硫必利组接受盐酸硫必利片治疗。比较两组患儿临床治疗效果,分析治疗前、后两组患儿T淋巴细胞亚群(CD3+、CD3+CD4+、CD4+/CD8+)值、神经递质[多巴胺(DA)、去甲肾上腺素(NE)、5羟色胺(5-HT)]水平变化差异。记录两组患儿治疗过程中出现嗜睡、头晕、恶心、失眠、乏力等不良反应发生概率。结果:硫必利组总有效率为81.6%(31/38),阿立哌唑总有效率为97.4%(37/38),与硫必利组相比,阿立哌唑组总有效率更高(P<0.05)。治疗前,两组CD3+、CD3+CD4+、CD4+/CD8+值比较未见显著差异,治疗后两组CD3+、CD3+CD4+、CD4+/CD8+值均上升,且阿立哌唑组上升更明显(P<0.05)。治疗前,两组DA、NE、5-HT水平比较未见显著差异,治疗后两组DA、NE、5-HT水平均下降,且阿立哌唑组下降更明显(P<0.05)。阿立哌唑组共计有2例患儿出现治疗不良反应,发生率为5.3%(2/38),硫必利组共计有8例患儿出现治疗不良反应,发生率为21.1%(8/38),与硫必利组相比,阿立哌唑组不良反应总发生率更低(P<0.05)。结论:阿立哌唑与硫必利在治疗抽动障碍方面均有较好疗效,但阿立哌唑对T淋巴细胞亚群、神经递质改善更好,且安全性更高。
Abstract
【Abstract】 Objective: To compare and analyze the effects of aripiprazole and tiapride on the efficacy, T lymphocyte subsets and neurotransmitters of children with tic disorder. Methods: 76 children with tic disorders who were admitted to our hospital from September 2020 to September 2022 were selected as the study subjects. They were divided into Aripiprazole (38 cases) and Tiapride (38 cases) according to the method of random number table. Tiapride was treated with Tiapride hydrochloride tablets and Aripiprazole was treated with Aripiprazole tablets. Compare the clinical treatment effect of the two groups of children, and analyze the differences in the levels of T lymphocyte subsets (CD3+, CD3+CD4+, CD4+/CD8+) and neurotransmitters [dopamine (DA), norepinephrine (NE), 5-hydroxytryptamine (5-HT)] before and after treatment. The occurrence probability of adverse reactions such as drowsiness, dizziness, nausea, insomnia and exertion during the treatment was recorded. Results: The total effective rate of Tipiride group was 81.6% (31/38), and the total effective rate of aripiprazole was 97.4% (37/38). Compared with Tipiride group, the total effective rate of aripiprazole group was higher (P<0.05). Before treatment, there was no significant difference in the values of CD3+, CD3+CD4+and CD4+/CD8+between the two groups. After treatment, the values of CD3+, CD3+CD4+and CD4+/CD8+increased in both groups, and the increase was more significant in aripiprazole group (P<0.05). Before treatment, there was no significant difference in the levels of DA, NE and 5-HT between the two groups. After treatment, the levels of DA, NE and 5-HT in the two groups decreased, and the decrease in aripiprazole group was more significant (P<0.05). A total of 2 children in the aripiprazole group had adverse reactions to treatment, with an incidence of 5.3% (2/38), and 8 children in the thiopiride group had adverse reactions to treatment, with an incidence of 21.1% (8/38). Compared with the thiopiride group, the total incidence of adverse reactions in the aripiprazole group was lower (P<0.05).Conclusion:Both aripiprazole and tiapride have good efficacy in the treatment of tic disorders, but aripiprazole has better improvement in T-lymphocyte subsets and neurotransmitters, and higher safety.
关键词
【关键词】 阿立哌唑;硫必利;抽动障碍;疗效;T淋巴细胞亚群;神经递质
KeyWord
【Key words】 Aripiprazole; Thiopride; Tic disorder; Efficacy; T lymphocyte subgroup; Neurotransmitter
基金项目
页码 442-445
  • 参考文献
  • 相关文献
  • 引用本文

于京虎*. 阿立哌唑与硫必利对抽动障碍患儿疗效及T淋巴细胞亚群、神经递质的影响 [J]. 国际精神病学杂志. 2024; 51; (2). 442 - 445.

  • 文献评论

相关学者

相关机构